Slide 1: Building the Next Immunology Leader
Building the Next Immunology Leader Last Updated: June 2023 zurabio Corporate Overview
Slide 2: Forward Looking Statements Disclaimer
Disclaimer Forward Looking Statements Disclaimer This communication includes “ forward - looking statements ” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 . Words such as “ expect ,” “ estimate ,” “ project ,” “ budget ,” “forecast,” “ an
Slide 3: Investment Highlights
Multiple Phase 2 programs • Validated mechanisms pursuing innovative new development paths • Potential Best - in - Class attributes combined with strategic clinical development to enhance differentiation Experienced and proven leadership • Experienced drug developers and asset hunters led by ex - Ar
Slide 4: Zura Company Timeline
Zura Company Timeline 4 MARCH 2022 Zura in - licensed ZB - 168, an anti - IL7R α antibody, from Pfizer* MARCH 2023 Zura completed business combination transaction with JATT Acquisition Corp; shares began trading under ticker ZURA on the NASDAQ JANUARY 2022 Zura is established DECEMBER 2022 Zura in -
Slide 5: An Experienced Leadership Team from A to Z
An E xperienced L eadership T eam from A to Z 5 Gary Whale Ph.D. Chief Technology Officer Mike Howell Ph.D. Chief Scientific Officer and Head of Translational Science Verender Badial Chief Financial Officer Amit Munshi Chairman Someit Sidhu M.D. Chief Executive Officer and Director Chris Cabell M.D.
Slide 6: Business Development Aligns with Philosophy of Developing Validated Mechanisms
Zura’s Business Development Aligns with its Philosophy of Developing Validated Mechanisms in Novel Ways 6 Pursue clinically validated mechanisms In - license assets with best - in - class potential to improve on first entrants Identify indications with unmet need and market opportunity Execute effic
Slide 7: Clinical stage pipeline targeting key immunology pathways
Clinical stage pipeline targeting key immunology pathways Current financing will bring in ZB - 106 as lead asset for Zura Candidate Indication Discovery Pre - clinical IND Phase 1 Phase 2 Phase 3 tibulizumab Anti BAFFxIL17 Tested through Ph1b INITIAL FOCUS: Systemic Sclerosis INITIAL FOCUS: Hidraden
Slide 8: Tibulizumab (ZB-106) is a Potential First-in-Class Dual Antagonist
Strictly Private and Confidential Tibulizumab (ZB - 106) is a Potential First - in - Class, Dual Antagonist Combining tabalumab and ixekizumab (TALTZ®) 8 ZB - 106 is an IgG - scFv engineered by the fusion of ixekizumab (TALTZ®) and tabalumab 1,2 • ZB - 106 neutralizes IL - 17A or BAFF regardless of
Slide 9: Eli Lilly Deal Terms
Strictly Private and Confidential Eli Lilly Deal Terms 9 Terms of Tibulizumab (ZB - 106) License Upfront: • Mid - teens upfront cash payment for exclusive global license Milestones: • Single digit development milestones • Back - end milestones triggered at approval and sales - based • Single to low
Slide 10: Clinical Development: Upcoming milestones
Strictly Private and Confidential Clinical Development 10 tibulizumab (BAFFx17) • 2 clinical studies for ZB - 106 • Initiate phase 2 study in Systemic Sclerosis (2024) • Initiate phase 2 study in Hidradenitis Suppurativa (2024) ZB - 168 (IL - 7R a ) • Advance CMC program for ZB - 168 ready to initia
Slide 11: ZB-106: Potential First-in-Class, Dual Antagonist
Strictly Private and Confidential ZB - 106: Potential First - in - Class, Dual Antagonist Combining tabalumab and Taltz 11 Note: please see language in the Disclaimer regarding ‘forward - looking statements’
Slide 12: IL-17 and BAFF Approved in Multiple Autoimmune Diseases
Strictly Private and Confidential IL - 17 IL - 17 / BAFF BAFF / TACI / APRIL Company Asset Cosentyx (secukinumab) Taltz (ixekizumab) Izokibep Sonelokimab ZB - 106 Benlysta (belimumab) Telitacicept BION - 1301 Atacicept MoA IL - 17A IL - 17A IL - 17A/A IL - 17A/F IL - 17A / BAFF BAFF TACI fc APRIL BA
Slide 13: ZB-106 is a Combination of Two Compounds with Demonstrated Efficacy
Strictly Private and Confidential TABALUMAB IXEKIZUMAB (TALTZ®) ZB - 106 is a Combination of Two Compounds that have Each Demonstrated Efficacy with an Established Safety Profile ▪ Taltz® (ixekizumab) is an approved anti IL - 17 therapy with estimated peak sales >$3bn ▪ tabalumab is an anti - BAFF w
Slide 14: ZB-106 Has Broad Potential Therapeutic Applications
Strictly Private and Confidential BAFF IL - 17 ZB - 1 06 H as B road Potential Therapeutic A pplications ▪ Potential to be a first - in - class biologic in a number of autoimmune diseases where both BAFF and IL - 17 are implicated in the pathology 1,2 • Systemic Sclerosis • Sjögren’s Syndrome • Syst
Slide 15: ZB-106 Disrupts IL-17 and/or BAFF-Mediated Inflammation
Strictly Private and Confidential ZB - 106 Disrupts IL - 17 and/or BAFF - Mediated Inflammation 15 BAFF Binds to BAFF trimer and BAFF 60 - mer preventing binding to BAFF - R, TACI, and BCMA 2 IL - 17 Binds to IL - 17A preventing IL - 17A/A and IL - 17A/F heterodimerization 1 T - cell and B - cell sy
Slide 16: ZB-106 Independently Neutralizes IL-17 or BAFF
Strictly Private and Confidential ZB - 106 (LY3090106) Independently Neutralizes IL - 17 or BAFF 16 6 Key Biology [Antibody] pM 1 10 100 1000 10000 100000 % I n h i b i t i o n C X C L 1 -40 -20 0 20 40 60 80 100 120 LSN3090106 Positive Control Negative Control LSN3090106+BAFF Positive Control+BAFF
Slide 17: ZB-106 Inhibits IL-17 or BAFF-Mediated Inflammation
Strictly Private and Confidential ZB - 106 (LY3090106) Inhibits IL - 17 or BAFF - Mediated Inflammation 17 ZB - 106 inhibits IL - 17 mediated CXCL1 production in C57Bl/6 mice similar to ixekizumab (positive control) 1 ZB - 106 reduces total B cell counts in the spleens of human BAFF transgenic mice
Slide 18: Combining IL-17 and BAFF Neutralization in a Murine Model of Arthritis
Strictly Private and Confidential Combining IL - 17 and BAFF Neutralization in a Murine Model of Arthritis Enables Improvement in Therapeutic Benefit 18 Biological mechanisms of BAFF/IL-17 Indication: • This molecule has the potential to be a first in class biologic in a number of autoimmune disease
Slide 19: ZB-106 is Clinically De-Risked Through P1b
Strictly Private and Confidential 19 ZB - 106 is Clinically De - Risked Through P1b 78 Subjects/Patients Dosed Across 3 P1/1b studies Pharmacokinetics Pharmacodynamics Safety and ADA • t 1/2 is 26.9 days • Bioavailability after SC doses was 62.9% • At doses tested there is evidence of maximum target
Slide 20: ZB-106: Systemic Sclerosis
Strictly Private and Confidential ZB - 106: Systemic Sclerosis 20 Note: please see language in the Disclaimer regarding ‘forward - looking statements’
Slide 21: Overview of Systemic Sclerosis
Strictly Private and Confidential Overview of Systemic Sclerosis ▪ Systemic sclerosis (SSc) remains among the deadliest of the rheumatic diseases ▪ Patients with SSc often have severe disability, fibrosis - related organ failure, and die prematurely • Up to 50% develop interstitial lung disease (ILD
Slide 22: Overview of Systemic Sclerosis Potential Opportunity
Strictly Private and Confidential 1. Health Advanced, LLC; Lenabasum Commercial Market Assessment 2. Tyndall et al, 2010 3. Bergamasco, A. et al., Clin Epidemi ol. 2019 Apr 18;11:257 - 273 4. Zura Bio internal analysis and benchmarking 5. Internal assumption based on demand research and rare disease
Slide 23: IL-17 and BAFF Inhibition Have Shown Efficacy in SSc
Strictly Private and Confidential IL - 17 and BAFF Inhibition Pathways Have Shown Efficacy in Placebo Controlled Trials in Systemic Sclerosis (SSc) 23 Stromal cells T1 - IFN BAFF Plasma cell CXCR5 + T fh cell TLS GC B cell CXCL13 IL - 17 efficacy in SSc • Brodalumab treatment in SSc leads to improve
Slide 24: Brodalumab Treatment in SSc Has Demonstrated Improved Clinical Outcomes
Strictly Private and Confidential Brodalumab Treatment in SSc has Demonstrated Improved Clinical Outcomes 24 • Brodalumab achieved the primary endpoint (treatment difference of least square mean: −21.2 [95% CI - 23.9, 18.5]; P<0.0001), and demonstrated a rapid, sustained reduction in mRSS over 52 we
Slide 25: Belimumab Treatment in SSc Has Demonstrated Improved Clinical Outcomes
Strictly Private and Confidential Belimumab Treatment in SSc has Demonstrated Improved Clinical Outcomes 25 • 52 - week, investigator initiated, single center, double blind, placebo - controlled pilot study • 20 subjects with dcSSC on MMF treated with belimumab or placebo • No significant difference
Slide 26: Rituximab in SSc Shows Efficacy
Strictly Private and Confidential Rituximab in SSc shows efficacy • Multiple Studies have shown the potential effectiveness of Rituximab in SSc – mainly open label and observational studies • The most compelling data come from the DESIRES double blind – placebo controlled trial 1 – Fifty - six patie
Slide 27: Proposed Phase 2 Trial Design
Strictly Private and Confidential Proposed Phase 2 Trial Design 27 • mRSS 10 - 29 • Subject presented the first symptoms of sclerosis other than Raynaud's phenomenon within 60 months before enrollment • Change mRSS • CRISS • SHAQ DI • VAS (RP, Pain, Ulcers, Breathing) • FVC, DLCO • PK / PD assessmen
Slide 28: ZB-106: Hidradenitis Suppurativa
Strictly Private and Confidential ZB - 106: Hidradenitis Suppurativa 28 Note: please see language in the Disclaimer regarding ‘forward - looking statements’
Slide 29: Overview of Hidradenitis Suppurativa
Strictly Private and Confidential Overview of Hidradenitis Suppurativa ▪ Hidradenitis Suppurativa is an inflammatory follicular skin disease ▪ Skin lesions develop in axillae, in the groin, and under the breasts, are formed as a result of inflammation & infection of sweat glands and are characterize
Slide 30: Overview of Hidradenitis Suppurativa Opportunity
Strictly Private and Confidential Overview of Hidradenitis Suppurativa Opportunity Despite Multiple IL - 17 Development Programs, There is Significant Opportunity to Address Unmet Need in HS 1 Drug Approved First in Class Therapy With Transformational Potential • Known efficacy of IL - 17 • Strong r
Slide 31: Significant Opportunity to Address Unmet Need in HS
Strictly Private and Confidential 31 Despite Multiple IL - 17 Development Programs, There is Significant Opportunity to Address Unmet Need in HS ZB - 106 may address the efficacy gap raised for current IL - 17 approaches in HS IL - 17 A/F hypothesis still remains to be proven in the clinic • IL - 17
Slide 32: Public Data in Multiple P3 Studies Shows IL-17 Validated in HS
Strictly Private and Confidential 32 Public Data in Multiple P3 Studies Shows IL - 17 is Clinically Validated Pathway to Treat HS TNF- α IL-17A IL-17A/F IL-17A/A SC SC / IV SC SC PIONEER I & II Phase 3 SUNSHINE & SUNRISE Phase 3 BE HEARD I & II Phase 3 Phase 2b Part A Open- Label 40mg QW for 12W 300
Slide 33: Addition of BAFF has Potential to Provide Superior Efficacy
Strictly Private and Confidential Addition of BAFF has Potential to Provide Superior Efficacy to IL - 17 Alone 33 • Increased BAFF expression in HS lesions and tunnels 2 - 4 • Lesional upregulation of BAFF and BAFF receptors is attributed to B cells and plasma cells 2,4 • Neutralization of BAFF with
Slide 34: SYK Antagonism in HS Demonstrates Clinical Efficacy
Strictly Private and Confidential Rituximab • Chimeric mAb to CD20, upon binding triggers cell death • Used off label in a range of autoimmune diseases • Case reports in HS (systematic review 2023) 1 – Majority with complete remission when treated with Rituximab did not respond to previous therapy i
Slide 35: Dermal Tunnels: Role in HS Pathogenesis
Strictly Private and Confidential 35 Dermal Tunnels: Role in HS Pathogenesis 1. Frew et al. 2021 Clin Exper Derm; 2. Sabat et al JACI 2023; 3 . Moran et al. JID 2017; 4 . Gudjonsson et al. 2020; 5. Jepsen et al. 2023. JAAD. • Recent literature highlights the role of dermal tunnels in the pathogenesi
Slide 36: ZB-106 in HS Clinical Development Plan Rationale
Strictly Private and Confidential ZB - 106 in Hidradenitis Suppurativa Clinical Development Plan Rationale 36 Opportunity for superior clinical response based upon IL - 17 + BAFF inhibition ▪ IL - 17 blockade in HS is a validated target with clear evidence of efficacy ▪ HiSCR50 at 16 weeks tends to
Slide 37: Proposed Phase 2 Trial Design
Strictly Private and Confidential Proposed Phase 2 Trial Design ~40 patients per arm ZB - 106 Dose level 1 ZB - 106 Dose level 2 Primary efficacy period (16 weeks) • Moderate to Severe HS • Hurley Stage II/III • Total abscess and inflammatory count (AN) ≥ 3 • HiSCR (50, 75, 100) • Improvement in bas
Slide 38: ZB-106: Optionality in additional indications
Strictly Private and Confidential ZB - 106: Optionality in additional indications 38 Note: please see language in the Disclaimer regarding ‘forward - looking statements’
Slide 39: Multiple External Readouts Validate IL-17 and BAFF Pathways
Strictly Private and Confidential Multiple External Readouts Continue to Validate Both IL - 17 and BAFF Pathways in Additional Diseases 39 Unmet need Evidence validating relevance of IL - 17 and BAFF inhibition External data readouts Sjögren's syndrome (SS) • It is estimated that there are 250,000 –
Slide 40: ZB-168: A Potential Best-in-Class Anti-IL7R
ZB - 168: A Potential Best - in - C lass A nti - IL7R Inhibiting Both IL7 and TSLP Pathways 40 Note: please see language in the Disclaimer regarding ‘forward - looking statements’
Slide 41: ZB-168 Asset Overview
ZB - 168 – Asset Overview 41 About ZB - 168 • IL7R α implicated in two key immune pathways 1 : IL7 and TSLP • Only anti - IL7R program to date with human clinical data showing impact on key T - cell sub - populations 2 • Well tolerated in >90 subjects and patients dosed in Phase 1 studies conducted
Slide 42: ZB-168 Enables Broad Impact by Targeting both TSLP and IL-7
ZB - 168 Enables Broad Impact on Epithelial - Driven Inflammation by Targeting both TSLP and IL - 7 1. Ebina - Shibuy, 2022. Nat Rev Immunol, 2. Marone, 2019. Expert Opin Investig Drugs, 3. Menzies - Gow, 2020. Respir Res, 4. Ch e n, 20 21 . Frontiers Immunol , 5. Herold, 2019 JCI Insight, Graphic c
Slide 43: ZB-168 Has Broad Potential Therapeutic Applications
I L7 TSLP is an early player in triggering airway inflammation via the activation of several immune cells such as den dritic cells, innate lymphoid cells, monocytes, macrophages and mast cells 5 Inhibition of IL7R promotes a normalisation in T reg :T effector T - c ell ratios 4 T SLP ZB - 168 IL7Rа I
Slide 44: ZB-168 is Potential Best-in-Class and Only Non-Partnered IL7Rα Asset
ZB - 168 is Potential Best - in - Class and Only Non - Partnered IL7R α Asset in Development 44 ZB - 168 ADX - 914 OSE - 127 GSK2618960 Tezepelumab UPB - 101 Type of A ntibody Human Human Humanised Humanised Human Human Target IL7R α IL7R α IL7R α IL7R α TSLP TSLPR 1 Mode of A dministrati o n SC 2 S
Slide 45: ZB-168 is Potentially Best-in-Class Asset at TSLP Inhibition
ZB - 168 is Potentially Best - in - Class Asset at TSLP Inhibition 45 1. Zura Internal D ata , 2. doi: 10.1172/jci.insight.126054, 3. doi : https://doi.org/10.1124/jpet.121.000686 , 4. BMS patent https://patents.google.com/patent/WO2020154293A1/en Asset ZB - 168 (IL7R α ) UPB - 101 ( α - TSLPR) Teze
Slide 46: Clinical data demonstrates impact on key T-cell subpopulations
46 Clinical data in patients demonstrates impact on key T - cell subpopulations ZB - 168 is Further Differentiated by T effector Cell Inhibition 1. doi: 10.1172/jci.insight.126054, 2. doi:10.1208/s12248 - 019 - 0401 - 3 • Up to 70% reduction in CD8+ T effector memory cells • Similar reductions seen
Slide 47: Summary of Clinical Data
Summary of Clinical Data 47 • 93 subjects dosed with ZB - 168 to date, including 33 patients with Type 1 Diabetes 1 and Multiple Sclerosis 2 • In Phase 1 single ascending dose study, ZB - 168 was generally well tolerated with no deaths and no subjects discontinued, or dose reduced due to Adverse Eve
Slide 48: Torudokimab: Targeting Anti-IL33
t orudokimab: T argeting A nti - IL33, an Alarmin with P otential in M ultiple I ndications 48 Note: please see language in the Disclaimer regarding ‘forward - looking statements’
Slide 49: Torudokimab Asset Overview
torudokimab – Asset Overview 49 1. Suzanne Cohen et al. 2015 Nature, 2. https://clinicaltrials.gov/ct2/show/NCT03913260; https://clinicaltrials.gov/ct2/show/NCT03343587; https://clinicaltrials.gov/ ct2 /show/NCT03831191, Section 6.1, DSUR for period 23 - Sep - 2019 to 22 - Sep - 2020, 3. Okragly et
Slide 50: Targeting IL-33 In Epithelial Driven Diseases
Targeting IL - 33 In Epithelial Driven Diseases 50 IL33 allergens IL25 TSLP PGD 2 Histamin proteases IL6 IL5 GM - CSF IL13 TNFa IL9 IL13 IL4 IL5 IL 4 IL 5 IL 9 IL 13 IL2 IFN γ IFN γ TCR IL13 IL5 Amphiregulin bacteria viruses o t h IL - 33 Pathway • IL - 33 is a member of the IL1 cytokine family that
Slide 51: Torudokimab Has Potential for Best-in-Class Activity
Source: Zura Bio Internal data torudokimab Has Potential for “Best - in - Class” Activity Torudokimab was 2.9 and 5.5 fold more potent than etokimab and itepekimab, respectively, inhibiting IL - 33 - induced GM - CSF product ion by human mast cells Antibody k on (M - 1 s - 1 ) k off (s - 1 ) k d (pM
Slide 52: Summary of Clinical Data
Summary of Clinical Data 52 • >100 subjects dosed with torudokimab to date, including in a Phase 2 trial in atopic dermatitis 1 • In Phase 1 study, torudokimab was well tolerated and no safety concerns were identified in either the SAD or MAD portions • The target engagement evaluation suggested bin
Slide 53: Building the Next Immunology Leader
Building the Next Immunology Leader Last Updated: June 2023 zurabio Corporate Overview